Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00347802
First received: June 30, 2006
Last updated: May 30, 2007
Last verified: May 2007
  Purpose

To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.


Condition Intervention Phase
Glaucoma
Drug: Bimatoprost 0.03%, Travoprost 0.004%
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Naive to treatment or washed off any ocular hypotensive agents
    • Untreated IOP >19 mm Hg
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete study

Exclusion Criteria:

  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study
    • History of intraocular surgery within the last 3 months
    • Prior discontinuation of any of the study medications for reasons related to efficacy or safety
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00347802

Locations
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00347802     History of Changes
Other Study ID Numbers: 5176
Study First Received: June 30, 2006
Last Updated: May 30, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Travoprost
Bimatoprost
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014